Actym Therapeutics, a biotech focused on the discovery and development of novel cancer therapies, and Wacker Biotech, have signed a contract for the manufacturing of Actym’s lead clinical candidate, ACTM-838, for the treatment of solid tumors. Wacker Biotech will initiate GMP (Good Manufacturing Practice) production of Phase 1 clinical material of Actym’s therapeutic candidate at its site in Amsterdam using its LIBATEC technology. Both companies announced today that they are alrea...